Full Text
ND2 MODELING THE COST-EFFECTIVENESS OF A NEW TREATMENT FOR MS (NATALIZUMAB) COMPARED TO CURRENT STANDARD PRACTICE IN SWEDEN

Abstract

Authors

G Kobelt J Berg P Lindgren J Hillert

Back to Volume 10, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×